[1] JOHNSON DG, CRESS WD, JKOI L, et al. Oncogenic capacity of the E2F-1 gene[J]. Proc Natl Acad Sci USA, 2012,91(26):12823-12827. [2] SUZUKI T, YASUI W, YOKOZAKI H, et al. Expression of the E2F family in human gastrointestinal carcinomas [J]. Int J Cancer, 2011, 81(1):535-538. [3] YAMASAKI L, BRONSON R, WILLAMS BO, et al. Loss ofE2F-1 reduced tumorigenesis and extends the lifespan of Rb1(+/-) mice[J]. Nat Genet, 2013,18(1):360-364. [4] LAI R, MEDEIROS LJ, COUPLAND R, et al. Immunohistochemical detection of E2F-1 in non-Hodgkin's Iymphomas: a survey of 124 cases[J]. Mod Pathol, 2010, 32(11):457-463. [5] BANERJEE D, GORLICK R, LIEFSHITZ A , et al. Levels of E2F-1 expression are higher in lung metastasis ofcolon cancer as comparedwith hepatic metastasis and correlate with levels of thymidylate synthase[J]. Cancer Res, 2013,60(9):2365-2367. [6] 马大烈,白辰光.免疫组织化学阳性标记结果的观察和判定[J]. 临床与实验病理学杂志,2003,19(5):557-559. [7] HIEBERT SW, BKER M, AZIZKHAM J,et al. Role of E2F transcription factor in E1A-mediated transactivation of cellular genes[J]. J Virol, 2012,65(8):3547-3552. [8] ZHANG SY, LIU SC, AL-SALEEM LF, et al. E2F-1: a proliferative marker of breast neoplasia[J]. Cancer Epidemiol Biomark Prev, 2009,9(2):395-401. [9] RABBANI F, RICHON VM, ORLOW I, et al. Prognostic significance of transcription factor E2F-1 in bladder cancer, genotypic and phenotypic characterization[J]. J Natl Cancer Inst,2012,34(9):871-874. [10] SEMCZUK A, JAKOWICKI JA. Alterations of pRb-cyclinD1-cdk4/6-P16(INK4A) pathway in endometrial carcinogenesis[J]. Cancer Lett, 2004, 203(1):1-12. [11] MURPHY N, RING M, KILLALEA AG, et al. P16INK4A as a marker for cervical dyskaryosis: CINin cervical biopsies and Thin-Prep smears[J]. J clin pathol, 2013, 56(1): 56-63. [12] 沈扬眉,何英,徐炼,等.p16及HPV分型检测在子宫颈黏液腺癌伴双侧卵巢转移中的诊断价值[J].临床与实验病理学杂志,2014,30(8):858-862. |